CAS No. |
920014-72-8 |
|---|---|
中文名称 |
(4R,7S,10S,13R,16S,19R,22R)-16-[(1H-咪唑-4-基)甲基]-7-[(1H-吲哚-3-基)甲基]-22-[(S)-2-乙酰氨基-5-胍基戊酰氨基]-13-苄基-10-(3-胍基丙基)-19-甲基-6,9,12,15,18,21-六氧代-1,2-二硫杂-5,8,11,14,17,20-六氮杂二十三元环-4-甲酰胺 |
英文名称 |
(4R,7S,10S,13R,16S,19R,22R)-16-((1H-imidazol-4-yl)methyl)-7-((1H-indol-3-yl)methyl)-22-((S)-2-acetamido-5-guanidinopentanamido)-13-benzyl-10-(3-guanidinopropyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosane-4-carboxamide |
别名 |
Setmelanodide;BIM-22493;IRC-022493);RM-493;RM-493; BIM-22493; IRC-022493);Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2→8)-disulfide;Setmelanotide (RM-493) trifluoroacetate salt |
标准英文名 |
(4R,7S,10S,13R,16S,19R,22R)-16-((1H-imidazol-4-yl)methyl)-7-((1H-indol-3-yl)methyl)-22-((S)-2-acetamido-5-guanidinopentanamido)-13-benzyl-10-(3-guanidinopropyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosane-4-carboxamide |
分子式 |
C49H68N18O9S2 |
分子量 |
1117.33 |
精确分子量 |
1116.49 |
SMILES |
CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)NC1=O |
标准SMILES |
CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2C=CC=CC=2)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](C)NC1=O)C(N)=O |
用途 |
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist that acts on human and rat MC4R; it has demonstrated positive efficacy in the treatment of obesity, having reached Phase 3 clinical trial endpoints. |
InChIKey |
HDHDTKMUACZDAA-PHNIDTBTSA-N |
|
|
评论 |
|---|